Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Medivir on its divestment of BioPhausia to Karo Pharma
Mandate

Vinge advises Medivir on its divestment of BioPhausia to Karo Pharma

November 03, 2016

Medivir AB (publ) (Nasdaq Stockholm) has entered into an agreement with Karo Pharma AB (publ) (Nasdaq Stockholm) regarding the sale of Medivir’s subsidiary BioPhausia (Nordic Brands) to Karo Pharma. The purchase price is SEK 908 million and the transaction is expected to close by mid-December 2016.
 
Vinge advises Medivir. The Vinge team includes Erik Sjöman, Anna Edström, Mattias Sköld, Dain Hård Nevonen, Rikard Lindahl and Ludvig Frithiof, and Fredrik Dahl and Sara Strandberg (employment law).

Related

Vinge advises Smart Eye Aktiebolag (publ) on its first SEK 300 million bond issue

 Vinge has advised Smart Eye Aktiebolag (publ) (“Smart Eye”) on the company’s first issue of senior unsecured bonds in an aggregate principal amount of SEK 300 million, under a framework of up to SEK 600 million. Skandinaviska Enskilda Banken AB (publ) acted as sole bookrunner in connection with the bond issue.
December 12, 2025

Vinge advises Nordstjernan in connection with the investment in Circura Group

Vinge has advised Nordstjernan in connection with its investment in newly established Circura Group.
December 12, 2025

Vinge has advised Axcel VI and Currentum in connection with the acquisition of Klarins Rör

 Vinge has advised Axcel VI and the Currentum Group in connection with the acquisition of Klarins Rör i Göteborg AB (“Klarins Rör”).
December 09, 2025